The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hopefully we'll see some positive results and SP go past 50p.
The recovery at Aim-traded Venture Life (VLG:51p), a developer, manufacturer and distributor of products for the self-care markets, is gathering traction.
A pre-close trading update for the year just ended was in line with my financial analysis three weeks ago when I made the case to buy the shares, at 40p (‘Venture Life’s recovery potential revealed’, 10 January 2022). Of more importance is news that the order book is “significantly ahead of the same time last year”, shipments with new China distribution partner have started, and two UK health and beauty retailers will be launching Venture’s lesser known in-house brands (for rosacea, women’s intimate gel, and wart & varruca pen) under their own labels. The group is also progressing an aggressive expansion plan for prostrate cancer management product Pomi-T.
Priced on a forward PE ratio of 11 for 2022, I maintain my 100p target. Buy.
why the drop never thought VLG had exposure to Russia?
Hi Agricore. I think one of us is misunderstanding the other. Your points:
1. I agree. I'm an example. Immunocompromised as I am I certainly wouldn't be going to the pub on a Saturday night, as I did the other day, without having found ways - like Dentyl - to minimise the risk.
2. Absolutely I agree, and that's why for me this is still so urgent. As I've said before, this is cheap, accessible right across the world, and it works.
3. Again I agree. I'm a believer!
4. I'm no expert, but I think both are essential - however peer review is no use without the numbers to review.
5. I truly hope so.
And I'm glad you mentioned the Chinese. They're not fools, they're worried sick about their poor vaccine + Omicron and progeny of, and may well pick up on this. If these competent marketers can get their act together for China VLG could as you say still do well. Meanwhile the rest of the world can go on breeding variants. I think Dentyl could help to stop that, my beef is that now we need another trial which will take forever.
Some quick thoughts on those details:
1. Surprised that they confined themselves just to hospital inpatients. No wonder they had trouble recruiting. So many outside also with viral loads in the saliva, far less worries about survival, and no co-morbidities. And given that - astonishingly to me - the only practical area where they seemed to be considering application was dental appointments then ambulant outpatients would seem to me to be more appropriate.
2. So with only 78 volunteers of which 27 had live virus (due to the time the disease had had to progress by the time they were in hospital), they had only enough patients for 6/7 for each of the 3 oral rinses they were testing plus the saline control: Normasol. Thus they were not going to achieve anything like useful statistical results.
3. VERY surprised indeed that "saliva was collected before rinsing (baseline), and at 1-, 15-, 30-, and 60-minutes post-rinsing", and not at say 12 and 24 hour periods afterwards, as well. For Dentyl normal use is twice a day, so 12 hour is very relevant.
4. Dentyl had 7 patients. IT WORKED. Far, far superior to the others. "Impressively, in 3/8 patients treated with Dentyl Dual Action, no live virus was recovered at any timepoint after the initial rinse" - but of course that is just up to 1 hour.
It appears that Dentyl just about wipes the throat clean, exactly as the in vitro results indicated 16 months ago. The virus does minimal harm in the throat, but while the throat is clean it will be far less likely to be passing the infection to the lungs where it does become dangerous, and while it builds up again the body is learning to fight it. That's what I think! And that's why I'm gutted that this trial is such a damp squib.
But at least - at last - finally - we have the results.....
For those willing to take the time to decipher it....!
"Although a subset of mouthwashes were effective in vitro, it was important to determine their effectiveness in vivo, where virus is being shed continually in the oropharynx. A randomised clinical trial was undertaken to measure the antiviral efficacy of mouthwashes following a 30 second rinse. 78 hospital in-patients with PCR-diagnosed COVID 19 were recruited, following invitation of over 400 to participate. Despite a positive PCR test in the preceding 14 days, only 27/78 patients had live SARS-CoV2 present in their baseline saliva. Recent studies show that live virus is almost never detected beyond 9 days post-symptom onset in immunocompetent patients (44). As our patients were ill enough to be admitted to hospital, many were likely beyond this timepoint. Unfortunately, this was not known at the time sample collection was initiated and only became evident towards the end, with the study terminated at 6 months. By then, new UK daily cases had decreased from 55,892 (31st Dec 2020) to 4,052 (31st March 2021), hospitalised patient numbers were declining and co-morbidity and ventilatory support in these patients rendered them ineligible for randomisation (https://coronavirus.data.gov.uk), making further recruitment impossible. Amongst patients with live virus, saliva was collected before rinsing (baseline), and at 1-, 15-, 30-, and 60-minutes post-rinsing, with mouthwashes containing either containing CPC/IPM (Dentyl Dual Action, n = 8), CPC/benzoate (SCD Ultra, n = 7), PVP-I (Videne, n = 6) or 0.9% w/v NaCl (Normasol, n = 6). Data is shown as both log2-fold reduction from baseline (Figure 5 D) and as individual patient data (Figure 6). Across the entire cohort, baseline salivary viral load varied widely, from 120 PFU/ml to 2.8 × 107 PFU/mL (Supplementary Data1.xls). All four mouthwashes reduced salivary viral load 1-minute post-rinsing, with the smallest reduction being from Normasol® (median 3.9 log2 fold reduction from baseline) and the largest Dentyl Dual Action where 6/7 patients recorded no live virus (median 14.3 log2 reduction from baseline) (Figure 5 D, Tables 3,4). The persistence of the effects varied with rinse. No significant reduction in salivary viral load was seen with Videne at any of the time-points, while for Normasol® a significant reduction was apparent only at 60 minutes. For SCD Ultra, a significant reduction in viral load was seen at 1 minute only (median 8.9 log2 reduction from baseline, Figure 5 D). Dentyl Dual Action was the only product to demonstrate a persistent effect, with a significant reduction evident throughout at 1, 15, 30 and 60 minutes respectively (medians 14.3, 11, 8.8, 9, log2 reduction from baseline). Impressively, in 3/8 patients treated with Dentyl Dual Action, no live virus was recovered at any timepoint after the initial rinse (Figure 6)."
I disagree with QD22 for a number of reasons:
1. Withdrawal of government support for covid testing - while there’s 50% who couldn’t give a monkeys and don’t wear masks etc there’s 50% who do. They will be actively looking for ways to minimise risk especially as wearing masks will become increasingly uncommon - for example goi g to a work meeting.
2. We are all assuming covid is “being lived with” all of a sudden. Didn’t we think that 6 months ago with delta? Then came omicron. So there’s no guarantee covid can’t whipsaw back again.
3. The fact this is further backed up elsewhere such as Salisbury hospital gives further credence
4. The fact that it is PEER REVIEWED is also key. This matters more than the size of the sample.
5. Id also point out vlg are competent marketers so I dare say they are executing product plans they had on stand by for today.
Meanwhile Chinese sales are other reasons for optimism and the forthcoming results are reasons for optimism next month….
Gla
Jatw, first, thank you for your earlier reply. I appreciated your measured kindness - especially in a total vacuum of any other response.
I wish I had time for a proper response - hopefully later.
First thoughts are that yes, what a crying shame the trial was so small.
In 40% of the hospitalised patients, who would have the virus all over it never came back. That's amazing.
In the rest the results were only for up to one hour later. Oh! 99.8% reduction overall. ie probably in most it was also completely eliminated.
Basically it's clear but not proven - as before, but much more so - that's it's a very effective first line of protection.
I am "immunologically compromised". I have been gargling nightly. I have nice fresh breath, clean gums (I'm sure my dentist on the breadline is DEVASTATED!), and am living a normal life!
Why wait for the trial? It's cheap and it's not going to hurt you. £1.99 in Home Bargains. Lasts for months, you use half a capful. Recommend the clove not the mint :) !
... are out and were successful. However, the sample is tiny (smaller than I appreciated) and further large scale trials are now required. Don't hold your breath (sic) for it to be an earner for VLG anytime soon.
QD22, you have the results…….interesting but the number of patients tested is not statistically sufficient.
The question now is do they do the large study……costs will be significantly more and may not generate sales….
This is not the future of the company so in my opinion they should pause testing..
The delay would suggest the trial was at best inconclusive and at worst a failure.
The vaccines have worked and there may be no sales bump to be gained now……best to let it go and be forgotten.
WHERE ARE THESE RESULTS?
18th November 2020, RNS:
"Today, the Company provides an update on the recently published[1] in-vitro results from a separate, independent laboratory study undertaken at Cardiff University by Dr Richard Stanton and his colleagues.
In their published in-vitro[2] study, scientists at Cardiff University concluded that Venture Life's two CPC based mouthwashes eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log reduction, equivalent to 99.999%) within a 30 second exposure."
1st December 2021, RNS:
"The Company continues to await the publication of the peer-reviewed in vivo study carried out by Cardiff University, which was completed in April this year. Whilst the Board is disappointed that this has taken longer than expected to publish, and does acknowledge that the timing is outside the control of Cardiff University, it is hopeful the final publication will be available soon. Further, the Company notes the recent announcement made by Salisbury Hospital regarding specific mouth care guidance for patients with Covid-19. As well as regular toothbrushing, the guidance also suggests that both Dentyl Dual Action and Dentyl Fresh Protect should be used. The Company understands this guidance was based on research conducted by Doctors at Salisbury Hospital, as well as the in-vitro (lab based) results widely published by Cardiff University in November 2020."
How is my throat going to be a fundamentally different environment from a test tube at the same temperature?
Open Orphan have been conducting trials where they infect volunteers with the virus deliberately: that way they can study the progress of the disease from day 1. According to one of the BBC science programmes (Inside Science?) that shows it starts in the throat, moves to the nose, then on. Gargling 1/2 X per day with something that kills 99.999% of the virus should therefore eliminate it or slow it down so much the body has no problem preparing for it and dealing with it. Thus effectively it would work as a free vaccine as well. It's CHEAP, it's EASY, it's already known as SAFE, it's already IN PRODUCTION, with DISTRIBUTION CHANNELS IN PLACE WORLDWIDE.
I emailed - politely - but got no answer.
I cannot see how this would not have saved many, many lives. The trial finished in APRIL.
Sometimes it's right to be very, very angry.
Simon Thompson tipped VLG on 31st January as follows (not posted here before):
"Penny drops with Venture Life
Share price rises 36 per cent following pre-close trading update
Order book significantly ahead of the same time last year
The recovery at Aim-traded Venture Life (VLG:51p), a developer, manufacturer and distributor of products for the self-care markets, is gathering traction.
A pre-close trading update for the year just ended was in line with my financial analysis three weeks ago when I made the case to buy the shares, at 40p (‘Venture Life’s recovery potential revealed, 10 January 2021). Of more importance is
news that the order book is “significantly ahead of the same time last year”,
shipments with new China distribution partner have started, and two UK health
and beauty retailers will be launching Venture’s lesser known in-house brands
(for rosacea, women’s intimate gel, and wart & varruca pen) under their own labels.
The group is also progressing an aggressive expansion plan for prostrate cancer
management product Pomi-T.
Priced on a forward PE ratio of 11 for 2022, I maintain my 100p target. Buy."
Took some more profit this morning …. Vlg is looking good!
I took some at 51.40…. very happy …. Will hold the rest!
it is time to take some profits from this morning 44p ,nice
yup growth up over 30% ..... I will cash in some Again ... but still think 60P in a few months!
Growth
DYOR
The tide can turn quickly with these v small cap companies.
Pre covid there was a steady self care business with excess manufacturing capacity.
They opportunistically started making hand sanitising gel (like many) for which there is now no margin (who cares), they also naively hyped a long term sales deal with China that could not be delivered (selling a western made chemical in China against local and copycat competition was alsways going to be a difficult task), the new China deal promises that VLG will be paid for what they sell which is a much sounder business. The core f the pre covid business is still there plus the two add ons.
We will need to see how the new products go…..I would prefer they don’t white label as that must mean a lot of value passes to the own brand and cannibalises the full price brand sales.
Market has probably overshot today by going over 50p…..but if your time horizon is several years it is probably a bargain.
...to sell.
It's a funny old company this one. When I compare the awful trading update of just 2 months ago against this one... it's bizarre... and I feel sorry for those who felt compelled in December.
looks very good this morning, 44p to buy
Indeed - great to see VLG updating and trading nicely in line, without any nasty surprises and everything appearing to be returning to a smoother path forward.
Good to see "the order book for the Group is significantly ahead of the same time last year".
And lots of progress product-wise:
"We are also pleased to report that a leading UK health and beauty retailer has confirmed they will launch our in-house developed product for rosacea in the UK and Ireland later in H1 2022 with the product being marketed under their own brand. This marks the first product launch under this retailer's own brand and paves the way for future collaboration. Furthermore, another key UK health and beauty retailer will launch our Wart & Verruca Pen and Women's Intimate Gel in H2 2022 under their own brand; finally, other new agreements have been recently completed for other products in other territories.
Following the successful integration of BBI Healthcare and Helsinn acquisitions, one of these new agreements has been signed for Pomi-T in Germany, which marks the start of the expansion plan of this product into key markets around the world, in another of the 5 major EU markets."